Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MNTA
CUSIP60877T10
Phone617-491-9700
Debt
Debt-to-Equity RatioN/A
Current Ratio6.65
Quick Ratio6.65
Price-To-Earnings
Trailing P/E Ratio-21.92
Forward P/E Ratio-14.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$138.88 million
Price / Sales15.14
Cash FlowN/A
Price / CashN/A
Book Value$4.90 per share
Price / Book5.48
Profitability
EPS (Most Recent Fiscal Year)($1.20)
Net Income$-88,090,000.00
Net Margins-128.49%
Return on Equity-40.55%
Return on Assets-30.87%
Miscellaneous
Employees279
Outstanding Shares78,320,000
Market Cap$2.03 billion
Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions
What is Momenta Pharmaceuticals' stock symbol?
Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."
How were Momenta Pharmaceuticals' earnings last quarter?
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) released its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.50. The biotechnology company had revenue of $13 million for the quarter, compared to analyst estimates of $15.83 million. Momenta Pharmaceuticals had a negative return on equity of 40.55% and a negative net margin of 128.49%. Momenta Pharmaceuticals's revenue was down 44.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.50) EPS. View Momenta Pharmaceuticals' Earnings History.
When is Momenta Pharmaceuticals' next earnings date?
What price target have analysts set for MNTA?
7 brokers have issued 12-month target prices for Momenta Pharmaceuticals' shares. Their predictions range from $14.00 to $24.00. On average, they expect Momenta Pharmaceuticals' share price to reach $17.00 in the next year. This suggests that the stock has a possible downside of 36.7%. View Analyst Price Targets for Momenta Pharmaceuticals.
What is the consensus analysts' recommendation for Momenta Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Momenta Pharmaceuticals.
Who are some of Momenta Pharmaceuticals' key competitors?
Some companies that are related to Momenta Pharmaceuticals include AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA) and Sangamo Therapeutics (SGMO).
Who are Momenta Pharmaceuticals' key executives?
Momenta Pharmaceuticals' management team includes the folowing people:
- Mr. Craig A. Wheeler, Pres, CEO, Principal Financial Officer, Principal Accounting Officer & Exec. Director (Age 58)
- Dr. Ganesh Venkataraman Kaundinya Ph.D., Co-Founder, COO, Chief Scientific Officer & Sr. VP (Age 51)
- Mr. Bruce A. Leicher J.D., Sr. VP, Gen. Counsel and Corp. Sec. (Age 62)
- Mr. Scott M. Storer, Sr. VP, CFO & Principal Accounting Officer (Leave of Absence)
- Dr. Santiago Arroyo M.D., Ph.D., Chief Medical Officer & Sr. VP of Devel.
Has Momenta Pharmaceuticals been receiving favorable news coverage?
News headlines about MNTA stock have trended positive on Thursday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a media and rumor sentiment score of 0.32 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 47.40 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Momenta Pharmaceuticals.
Who are Momenta Pharmaceuticals' major shareholders?
Momenta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.05%), FMR LLC (14.99%), RA Capital Management LLC (4.73%), Janus Henderson Group PLC (2.85%), Renaissance Technologies LLC (1.78%) and Fiera Capital Corp (1.41%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, James M Roach, Richard P Shea, Santiago Arroyo, Scott M Storer and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals.
Which institutional investors are selling Momenta Pharmaceuticals stock?
MNTA stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Renaissance Technologies LLC, Bank of New York Mellon Corp, Strs Ohio, Fisher Asset Management LLC, California Public Employees Retirement System, Municipal Employees Retirement System of Michigan and Arizona State Retirement System. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Santiago Arroyo, Scott M Storer and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals.
Which institutional investors are buying Momenta Pharmaceuticals stock?
MNTA stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management LLC, BlackRock Inc., Janus Henderson Group PLC, First Trust Advisors LP, FMR LLC, PNC Financial Services Group Inc., Bank of America Corp DE and Bank of Montreal Can. View Insider Buying and Selling for Momenta Pharmaceuticals.
How do I buy shares of Momenta Pharmaceuticals?
Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Momenta Pharmaceuticals' stock price today?
One share of MNTA stock can currently be purchased for approximately $26.85.
How big of a company is Momenta Pharmaceuticals?
Momenta Pharmaceuticals has a market capitalization of $2.03 billion and generates $138.88 million in revenue each year. The biotechnology company earns $-88,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Momenta Pharmaceuticals employs 279 workers across the globe.
How can I contact Momenta Pharmaceuticals?
Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]
MarketBeat Community Rating for Momenta Pharmaceuticals (NASDAQ MNTA)
MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe MNTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
